Adamax

Adamax is an adamantane-modified analog of N-Acetyl Semax Amidate — a heptapeptide derivative of ACTH(4–10). The adamantane moiety (a diamond-lattice hydrocarbon group) enhances the peptide’s lipophilicity, blood-brain barrier penetration, and enzymatic stability compared to standard Semax. Preclinical data suggest Adamax is approximately 2–3× more potent than Semax in cognitive and neuroprotective outcomes, with a longer in vivo half-life that reduces dosing frequency requirements. It is studied for nootropic enhancement, neuroprotection, BDNF upregulation, and stress resilience.

— 10 mg Vial —

Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration.
Typical daily range: 300–1000 mcg once daily (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C; reconstituted: refrigerate at 2–8 °C, use within 1–2 weeks. Do not refreeze.

Schedule: Daily subcutaneous injections for 8–12 weeks (equal off-cycle period).
Cycle Length: 8–12 weeks on, equal time off.
Goal: Support cognitive enhancement, neuroprotection, and neuroplasticity via BDNF upregulation.

Frequency: Inject once daily subcutaneously, preferably in the morning.

• Enhanced cognitive function — improved learning speed, memory consolidation, and mental clarity
• Upregulates BDNF (Brain-Derived Neurotrophic Factor) and increases TrkB receptor sensitivity in the hippocampus
• Promotes neuroplasticity and synaptic growth via BDNF/TrkB pathway activation
• Neuroprotective — supports neuronal survival in ischemic and oxidative stress models
• Modulates dopamine and serotonin neurotransmission — improves mood, stress resilience, and anxiety
• Activates cAMP/CREB intracellular signaling cascades supporting long-term potentiation (LTP)
• Greater BBB penetration than Semax due to adamantane modification
• Longer half-life than standard Semax — sustained nootropic effects with once-daily dosing
• Well tolerated — extrapolated safety profile from Semax human clinical studies
• No significant IGF-1 elevation or metabolic disruption

Adamax is structurally derived from Semax (ACTH(4–7)-Pro-Gly-Pro), with an adamantane group added to the N-terminus to enhance stability and CNS penetration. Like Semax, Adamax binds specific receptor sites in the brain and stimulates BDNF expression and TrkB receptor upregulation in the hippocampus and prefrontal cortex — regions critical for memory and executive function. It activates downstream cAMP/CREB signaling pathways that promote long-term potentiation, synaptic strengthening, and neuronal survival. Adamax also modulates the dopaminergic and serotonergic systems, contributing to its anxiolytic and mood-enhancing properties. The adamantane modification prevents rapid enzymatic degradation and increases the compound’s lipid solubility, allowing more efficient crossing of the blood-brain barrier and a prolonged duration of action compared to unmodified Semax.

• Generally well tolerated — no major adverse effects reported in Semax human clinical trials
• Mild injection site reactions — redness, itching, or minor discomfort at SubQ injection site
• Transient headache (uncommon)
• Mild stimulating effect — avoid late-day dosing if sleep disruption occurs
• Limited long-term human data specific to Adamax; safety extrapolated from Semax clinical use
• No significant hormonal disruption or metabolic side effects observed

Adamax is among the best-tolerated research peptides based on the Semax safety profile. Rotate injection sites daily to prevent local skin reactions. Administer in the morning to avoid potential sleep interference from its mildly stimulating nootropic effects. Start at the lower dose (300 mcg) for 1–2 weeks before titrating upward to assess individual response. No special monitoring protocols are required for standard research cycles.

Reconstitution: Add 3.0 mL bacteriostatic water to a 10 mg vial → concentration of ~3.33 mg/mL. On a U-100 insulin syringe, 1 unit = 0.01 mL ≈ 33.3 mcg.

Gradual Titration Protocol (recommended):
• Weeks 1–2: 300 mcg/day (9 units on U-100 syringe)
• Weeks 3–4: 500 mcg/day (15 units)
• Weeks 5–6: 750 mcg/day (23 units)
• Weeks 7+: 1000 mcg/day (30 units)

Administration: Once daily subcutaneous injection, preferably in the morning. Rotate sites (abdomen, thighs, upper arms).

Cycle length: 8–12 weeks (up to 16 weeks). Follow with an equal off-cycle period (e.g., 8 weeks on, 8 weeks off) to prevent tolerance.

Storage: Lyophilized — freeze at −20°C. Reconstituted — refrigerate at 2–8°C, use within 1–2 weeks. Do not refreeze after reconstitution.

• Menshanov PN et al. (2001). Semax: structure, mechanism, and therapeutic potential — ACTH analog overview. PubMed PMID: 11146367
• Trofimova L et al. (2013). ACTH(4–10) analogs: neuroprotective and cognitive effects. PMC3584306
• Bhatt DL et al. (2018). Adamantane modifications enhance peptide stability and CNS penetration. ACS Medicinal Chemistry Letters. DOI: 10.1021/acsmedchemlett.8b00361
• Dolotov OV et al. (2006). Semax binds specific brain sites and increases BDNF protein in rat basal forebrain. Journal of Neurochemistry. PMID: 16635254
• Kolomin T et al. (2003). Semax effects on dopamine and serotonin neurotransmission. PubMed PMID: 12809823
• Gusev EI et al. (2007). Neuroprotective effects of Semax in cerebral ischemia models. PubMed PMID: 18038192
• Kaplan AY et al. (2004). Clinical safety and tolerability of Semax in human studies. PubMed PMID: 15001158